US Broadcast: Tuesday, March 31, 2020 at 2pm EDT | 1pm CDT | 11am PDT
Asia Pacific: Wednesday, April 1, 2020 at 8:30am IST | 12pm JST | 2pm AEDT
Biotherapeutics such as monoclonal antibodies (mAbs) are frequently glycosylated, and the structure of attached N-glycans can affect immunogenicity, pharmacokinetics and pharmacodynamics. This can make glycosylation a critical quality attribute (CQA), making characterization of N-glycans an essential part of the development process. We present complete N-glycan quantitation workflow solutions using liquid chromatography (LC) with fluorescence detection (FLD) or mass spectrometry (MS) for four levels of biotherapeutic analysis: intact mass, mAb subunits, glycopeptides, and released glycans. Released N-glycans are labeled with InstantPC (a glycan dye that provides high FLD and MS signal) or 2-AB (a traditionally-used label) prior to separation by hydrophilic interaction liquid chromatography (UHPLC-HILIC). Sialylation of biotherapeutics can also be important, and we present a plate-based streamlined workflow for quantitation of total sialic acid.
Key Learning Objectives:
Who Should Attend:
For questions please contact Martha Devia: firstname.lastname@example.org